Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

A patient with refractory multiple myeloma received an infusion of CTL019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric antigen receptor, after myeloablative chemotherapy (melphalan, 140 mg per square meter of body-surface area) and autologous stem-...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:N Engl J Med
Prif Awduron: Garfall, Alfred L., Maus, Marcela V., Hwang, Wei-Ting, Lacey, Simon F., Mahnke, Yolanda D., Melenhorst, J. Joseph, Zheng, Zhaohui, Vogl, Dan T., Cohen, Adam D., Weiss, Brendan M., Dengel, Karen, Kerr, Naseem D.S., Bagg, Adam, Levine, Bruce L., June, Carl H., Stadtmauer, Edward A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4646711/
https://ncbi.nlm.nih.gov/pubmed/26352815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1504542
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg